DNR taisymo sistemos genų raiškos svarba numatant pacientų, sergančių 1b – 3a stadijų nesmulkialąsteliu plaučių vėžiu, pooperacinį gydymą

the incidence of lung cancer in lithuania and in the world is increasing. mortality from lung cancer in men in lithuania is ranked no. 1 among all deaths from cancer. contemporary treatment for radical surgery and adjuvant chemotherapy has reached its limits, regardless of the combination of drugs and their composition, the effectiveness of treatment is 20%. analyzing the clinical trials already performed, when the ercc1 and rrm1 genes were included and the treatment chosen for their expression and obtaining favorable results, and also in light of controversial authors' data, it is expedient to carry out additional molecular studies to determine the gene expression of the dna repair system. thus, a molecular diagnosis of a tumor is planned, an individual postoperative treatment of patients by choosing the optimal treatment regimen after progression of the disease through chemotherapy in order to obtain the best treatment results and predicting the possible further course of the disease. the study included 80 patients with stage 1b - 3a non-small cell lung cancer. the result obtained shows that the expression of the ercc1 gene in the blood after 4 months, the rrm1 gene expression in the blood after 4 months, the rrm1 gene expression in the blood after 12 months, rrm1 (-524c → t) gene polymorphism are independent predictors of survival of patients with non-small cell lung cancer factors. the shorter time to disease progression or relapse after treatment is directly related to the high expression of the ercc1 and rrm1 genes in the blood after postoperative chemotherapy. low levels of ercc1 and rrm1 gene expression in the bloodstream are directly related to better disease prediction and better response to postoperative treatment. only the rrm1 (-524c → t) gene polymorphism in the blood is associated with the progression of the disease after treatment